Click to go to U of C Home Page
Links Medical Genetics University of Calgary
Dr. P. Régine Mydlarski

MD, FRCPC
Assistant Professor
Director, Immunodermatology & Transplant Dermatology
Departments of Medicine, Medical Genetics and Pathology & Laboratory Medicine
Room 1871, Health Sciences Centre
Tel: (403) 210-3926     Fax: (403) 210-3949
Email: 
 
  
Research Interests
 
My laboratory investigates the pathogenesis and treatment of pemphigus vulgaris (PV), a potentially life-threatening autoimmune blistering disease of the skin and mucous membranes.  In collaboration with international researchers, we have developed a large pemphigus registry which comprises epidemiologic, serologic and molecular data. Our research focuses on the genetic basis of the disease, the role of autoantibodies in the pathogenesis of blistering lesions, the advancement of diagnostic techniques using addressable laser bead immunoassays (ALBIA), the study of existing therapies (notably intravenous immunoglobulin and rituximab) and the development of novel targeted therapies.
 

 Publications
  
1.     Zee JM, Shideler KK, Eystathioy T, Bruecks AK, Fritzler MJ and Mydlarski PR. GW bodies: novel cytoplasmic compartments in normal human skin. Submitted to J Invest Dermatol (December 2007).
 
2.     Blondin DA, Zhang Z, Shideler KK, Hou H, Fritzler MJ and Mydlarski PR. The prevalence of non-organ specific autoantibodies in patients with pemphigus vulgaris. Submitted to J Cutan Med Surg (December 2007).
 
3.     MydlarskiPR, DaviesS, ZhangZ, KrolA, TaherM, SteerBM, BjerknesM, MarsdenPA and Hogg D. Developmental second hits and the concept of a mutation field. Under revision for PLoS One (October 2006).
 
4.     Prajapati V and Mydlarski PR. Pretibial myxedema. Accepted in Can Fam Physician (May 2007).
 
5.     Prajapati V and Mydlarski PR. Tinea versicolor. Accepted in Can Fam Physician (September 2007).
 
6.     Prajapati V and Mydlarski PR. Rituximab: a B cell depletion therapy for dermatologic disease. Skin Therapy Lett 12(6):6-9, 2007.
 
7.     Mydlarski PR, Ho VC and Shear NH. A Canadian consensus statement on the use of intravenous immunoglobulin therapy in dermatology. J Cutan Med Surg 10(5):205-221, 2006.
 
8.     Mittmann N, Chan B, Knowles SR, Mydlarski PR, Cosentino L and Shear NH. The effect of intravenous immunoglobulin on prednisone dose in patients with pemphigus vulgaris. J Cutan Med Surg 10(5):222-227, 2006.

 
Research Funding
 
Canadian Dermatology Foundation
  • “The role of GW bodies in cutaneous squamous cell carcinomas” 2007-2009
  • “ A multiplexed fluorescent microsphere immunoassay for the detection of skin autoantibodies” 2005-2008
  • “Developmental second hits and the concept of a mutation field” 2004-2006
Talecris Talents Program
  • “A randomized double-blind, placebo controlled trial to assess the safety and efficacy of intravenous immunoglobulin in the treatment of pemphigus vulgaris” 2007-2010
Bayer Health Care
  • “Cytokine expression patterns in the serum of patients with pemphigus vulgaris” 2005-2007
Bayer Canada
  • “Burden of illness in pemphigus vulgaris” 2004-2006
Arthritis Society, Department of Medicine, Faculty of Medicine
  • “Translational research in pemphigus: start-up funds” 2004-2008



BACK
blank
blank
Edit Website